Arbekacin is a semisynthetic aminoglycoside antibiotic mainly used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus. Arbekacin was originally synthesized from dibekacin in 1973. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.

纯度：≥98%

CAS：51025-85-5